ACADIA Pharmaceuticals to Announce Third Quarter 2018 Financial Results on November 6, 2018

ACADIA to Host Conference Call and Webcast on Tuesday, November 6,
2018, at 5:00 p.m. Eastern Time

SAN DIEGO--(BUSINESS WIRE)--Oct. 23, 2018--
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company
focused on the development and commercialization of innovative medicines
that address unmet medical needs in central nervous system disorders,
today announced that it will report its financial results for the third
quarter ended September 30, 2018 on Tuesday, November 6, 2018, after the
U.S. financial markets close. ACADIA’s management will host a conference
call and webcast on Tuesday, November 6, 2018, at 5:00 p.m. Eastern Time
to discuss ACADIA’s financial results and operations.

The conference call may be accessed by dialing 855-638-4820 for
participants in the United States or Canada and 443-877-4067 for
international callers (reference passcode 3659459). A telephone replay
of the conference call may be accessed through November 20, 2018 by
dialing 855-859-2056 for callers in the United States or Canada and
404-537-3406 for international callers (reference passcode 3659459). The
conference call also will be webcast live on ACADIA’s website, www.acadia-pharm.com
under the investors section and will be archived there until November
20, 2018.

About ACADIA Pharmaceuticals

ACADIA is a biopharmaceutical company focused on the development and
commercialization of innovative medicines to address unmet medical needs
in central nervous system disorders. ACADIA has developed and is
commercializing the first and only medicine approved for the treatment
of hallucinations and delusions associated with Parkinson’s disease
psychosis. In addition, ACADIA has ongoing clinical development efforts
in additional areas with significant unmet need, including
dementia-related psychosis, schizophrenia inadequate response,
schizophrenia-negative symptoms, major depressive disorder and Rett
syndrome. This press release and further information about ACADIA can be
found at: www.acadia-pharm.com.

Forward-Looking Statements

Statements in this press release that are not strictly historical in
nature are forward-looking statements. These statements include but are
not limited to statements regarding the timing of future events. These
statements are only predictions based on current information and
expectations and involve a number of risks and uncertainties. Actual
events or results may differ materially from those projected in any of
such statements due to various factors, including the risks and
uncertainties inherent in drug discovery, development, approval and
commercialization. For a discussion of these and other factors, please
refer to ACADIA’s annual report on Form 10-K for the year ended December
31, 2017 as well as ACADIA’s subsequent filings with the Securities and
Exchange Commission. You are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
hereof. This caution is made under the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. All forward-looking
statements are qualified in their entirety by this cautionary statement
and ACADIA undertakes no obligation to revise or update this press
release to reflect events or circumstances after the date hereof, except
as required by law.